| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SLGC Stock Overview
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.
SomaLogic Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.43 |
| 52 Week High | US$14.72 |
| 52 Week Low | US$3.92 |
| Beta | 0 |
| 1 Month Change | -9.96% |
| 3 Month Change | -18.27% |
| 1 Year Change | -61.17% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay
SomaLogic (NASDAQ:SLGC) to acquire Palamedrix, an innovator in DNA nanotechnology, that provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that company intends to leverage as it develops the next generation of the SomaScan Assay. Under the terms of the merger agreement, company will pay at closing $35M, comprising $14M in cash and $21M in company stock. Up to an additional $17.5M may be paid in connection with the achievement of certain future revenue-based milestones. Transaction expected to close in Q3 and is not expected to contribute to revenue. As part of the transaction, company will obtain the intellectual property covering Palamedrix’s core DNA-based technology platform for the integration of molecular biosensors onto chips.
Shareholder Returns
| SLGC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -13.0% | 1.9% | 3.2% |
| 1Y | -61.2% | -19.8% | -10.1% |
Return vs Industry: SLGC underperformed the US Life Sciences industry which returned -20.2% over the past year.
Return vs Market: SLGC underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| SLGC volatility | |
|---|---|
| SLGC Average Weekly Movement | 10.8% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLGC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SLGC's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 320 | Roy Smythe | https://www.somalogic.com |
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company’s SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
SomaLogic Fundamentals Summary
| SLGC fundamental statistics | |
|---|---|
| Market Cap | US$807.55m |
| Earnings (TTM) | -US$82.04m |
| Revenue (TTM) | US$85.75m |
9.4x
P/S Ratio-9.8x
P/E RatioIs SLGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGC income statement (TTM) | |
|---|---|
| Revenue | US$85.75m |
| Cost of Revenue | US$81.59m |
| Gross Profit | US$4.16m |
| Other Expenses | US$86.20m |
| Earnings | -US$82.04m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 15, 2022
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 4.85% |
| Net Profit Margin | -95.68% |
| Debt/Equity Ratio | 0% |
How did SLGC perform over the long term?
See historical performance and comparisonValuation
Is SLGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SLGC?
Other financial metrics that can be useful for relative valuation.
| What is SLGC's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$807.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | -1.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SLGC's PS Ratio compare to its peers?
| SLGC PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.3x | ||
NSTG NanoString Technologies | 5.5x | 24.1% | US$789.5m |
BNGO Bionano Genomics | 44.8x | 53.0% | US$1.0b |
NEO NeoGenomics | 3.2x | 10.5% | US$1.6b |
QTRX Quanterix | 3.5x | 25.8% | US$386.9m |
SLGC SomaLogic | 9.4x | 27.5% | US$807.5m |
Price-To-Sales vs Peers: SLGC is good value based on its Price-To-Sales Ratio (9.4x) compared to the peer average (14.3x).
Price to Earnings Ratio vs Industry
How does SLGC's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Sales vs Industry: SLGC is expensive based on its Price-To-Sales Ratio (9.4x) compared to the US Life Sciences industry average (5x)
Price to Sales Ratio vs Fair Ratio
What is SLGC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9.4x |
| Fair PS Ratio | 4.3x |
Price-To-Sales vs Fair Ratio: SLGC is expensive based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (4.3x).
Share Price vs Fair Value
What is the Fair Price of SLGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SLGC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SLGC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is SomaLogic forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-0.04%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLGC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLGC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLGC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLGC's revenue (27.5% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: SLGC's revenue (27.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLGC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has SomaLogic performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-82.6%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SLGC is currently unprofitable.
Growing Profit Margin: SLGC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SLGC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SLGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLGC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.3%).
Return on Equity
High ROE: SLGC has a negative Return on Equity (-13.29%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is SomaLogic's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SLGC's short term assets ($689.6M) exceed its short term liabilities ($27.7M).
Long Term Liabilities: SLGC's short term assets ($689.6M) exceed its long term liabilities ($68.2M).
Debt to Equity History and Analysis
Debt Level: SLGC is debt free.
Reducing Debt: SLGC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLGC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SLGC has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.4% each year
Discover healthy companies
Dividend
What is SomaLogic current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SLGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLGC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLGC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SLGC has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Roy Smythe (60 yo)
3.75yrs
Tenure
US$14,305,529
Compensation
Dr. Roy Smythe, MD has been Chief Executive Officer of SomaLogic, Inc since joining in November 2018 and its Director since July 2021. During the course of his career, Dr. Smythe has been an internationall...
CEO Compensation Analysis
Compensation vs Market: Roy's total compensation ($USD14.31M) is above average for companies of similar size in the US market ($USD3.92M).
Compensation vs Earnings: Roy's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: SLGC's management team is considered experienced (2.6 years average tenure).
Board Members
Experienced Board: SLGC's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Top Shareholders
Company Information
SomaLogic, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: SomaLogic, Inc.
- Ticker: SLGC
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$807.548m
- Shares outstanding: 182.29m
- Website: https://www.somalogic.com
Number of Employees
Location
- SomaLogic, Inc.
- 2945 Wilderness Place
- Boulder
- Colorado
- 80301
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/12 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.